|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-21.82/11.36
|
Enterprise Value
9.51B
|
Balance Sheet |
Book Value Per Share
317.31
|
Cash Flow |
Cash Flow Yield
0.04
|
Income Statement |
Total Revenue
2.67B
|
Operating Revenue Per Share
95.37
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/14 11:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |